Study #2022-0486
A Phase I, Two-Part, Multicenter, Open-Label First in Human Study of anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants with Advanced Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
M9140, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
Description
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Cancer
Study phase:
Phase I
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-517-2078
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.